These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23546445)

  • 41. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
    Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
    JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aldosterone antagonism and myocardial infarction: from animals to man and back.
    Solomon SD; Pfeffer MA
    J Am Coll Cardiol; 2003 Nov; 42(9):1674-6. PubMed ID: 14607458
    [No Abstract]   [Full Text] [Related]  

  • 43. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
    Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
    Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction].
    Tsutamoto T
    Nihon Yakurigaku Zasshi; 2004 Aug; 124(2):90-100. PubMed ID: 15277727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.
    Mak GJ; Ledwidge MT; Watson CJ; Phelan DM; Dawkins IR; Murphy NF; Patle AK; Baugh JA; McDonald KM
    J Am Coll Cardiol; 2009 Oct; 54(18):1674-82. PubMed ID: 19850207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aldosterone Antagonism in Atrial Fibrillation: Implications for AF-Predominant HFpEF.
    Ho JE
    J Am Heart Assoc; 2020 Sep; 9(18):e018396. PubMed ID: 32909522
    [No Abstract]   [Full Text] [Related]  

  • 47. [Misdiagnosed emergency: heart failure symptoms after infarct. Rapid aldosterone block can safe the tired heart].
    MMW Fortschr Med; 2008 May; 150(22):48-9. PubMed ID: 18700263
    [No Abstract]   [Full Text] [Related]  

  • 48. Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction.
    Tannenbaum S; Sayer GT
    Curr Opin Cardiol; 2015 May; 30(3):250-8. PubMed ID: 25807227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. More hope for heart failure. Findings suggest expanded use of aldosterone-blockers.
    Aaronson K
    Health News; 2003 May; 9(5):4. PubMed ID: 12739453
    [No Abstract]   [Full Text] [Related]  

  • 50. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
    Kolloch R; Offers E
    MMW Fortschr Med; 2003 Nov; 145(47):42-4, 47. PubMed ID: 14725033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New treatment option for heart failure patients: eplerenone.
    Southworth MR; Cavallari LH
    J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety.
    Bomback AS
    Blood Purif; 2016; 41(1-3):166-70. PubMed ID: 26765793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
    Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eplerenone in mild heart failure.
    Tomaschitz A; Pilz S; März W
    N Engl J Med; 2011 Apr; 364(14):1371; author reply 1372. PubMed ID: 21470018
    [No Abstract]   [Full Text] [Related]  

  • 57. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
    Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J
    Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy.
    Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
    J Am Coll Cardiol; 2003 Feb; 41(4):574-81. PubMed ID: 12598068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Testani JM; Pandey A; Sambandam K; Drazner MH; Fang JC; Tang WHW
    Eur J Heart Fail; 2018 Oct; 20(10):1436-1443. PubMed ID: 29893446
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.